122 results
424B3
SEEL
Seelos Therapeutics Inc
15 Mar 24
Prospectus supplement
4:15pm
, Orphan Drug Designation (“ODD”) for OPMD and SCA3 has been secured in the United States and in the European Union (“EU”). In February 2019, we assumed
8-K
EX-10.1
SEEL
Seelos Therapeutics Inc
30 Jan 24
Entry into a Material Definitive Agreement
4:01pm
or its Subsidiaries’ employees is a member of a union that relates to such employee’s relationship with the Company or such Subsidiary, and neither
424B5
6xmn e5r1qastf
30 Jan 24
Prospectus supplement for primary offering
6:05am
424B5
sqiubtxrglb
30 Nov 23
Prospectus supplement for primary offering
4:58pm
424B5
r4yo9tsqs34kkn
28 Nov 23
Prospectus supplement for primary offering
4:06pm
424B3
d0y f90ey71o
29 Sep 23
Prospectus supplement
4:56pm
8-K
EX-10.1
f18vh
25 Sep 23
Entry into a Material Definitive Agreement
4:06pm
424B5
ve6zu22 sn9nan
25 Sep 23
Prospectus supplement for primary offering
6:02am
8-K
EX-1.1
igs38il4
12 May 22
Entry into a Material Definitive Agreement
8:31am